Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › arbaclofen

arbaclofen

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of arbaclofen

3 trials tracked of arbaclofen: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 2 citations.

3Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 1
  1. Phase 3 A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS Completed · 2 cited
  2. Phase 3 A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS Completed
  3. Phase 2 Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Arbaclofen Phase 3 Trials Establish Clinically Meaningful Change Thresholds in Fragile X Syndrome
Drug Pipeline Phase III
Arbaclofen Phase 3 Trials Establish Clinically Meaningful Change Thresholds in Fragile X Syndrome New Rules for Measuring Behavior Change in Fragile X
A review of two Phase 3 trials in 278 individuals with Fragile X Syndrome (aged 5-50 years) established clinically meaningful change thresho…
Imagine a parent watching their child struggle with daily routines.
Apr 24, 2026